iSpecimen’s Global Biospecimen Marketplace Surpasses 200 Suppliers
March 08 2022 - 7:30AM
iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), a
global, proprietary online marketplace connecting scientists with
healthcare providers to search for biospecimens needed for medical
research, today announced that the Company’s network has surpassed
200 healthcare providers.
The iSpecimen Marketplace is a novel technology platform that
connects life sciences researchers who need
biospecimens for their research with patients and healthcare
organizations that can provide these samples. The Marketplace
specifically addresses procurement inefficiencies that have
traditionally forced researchers to limit the scope of their work
due to the shortage of quality biospecimens. Researchers can search
for biospecimens based on demographic traits, medical conditions,
procedures, blood type, country of collection, and much more.
“Each of our suppliers, both individually and collectively, adds
tremendous value to our platform for the thousands of researchers
that use the iSpecimen Marketplace,” said Dr. Christopher Ianelli,
M.D., Ph.D., iSpecimen Founder and CEO. “Our network’s ongoing
expansion helps to maintain a steady flow of biospecimens to
researchers and helps to offset regional fluctuations that result
from a global pandemic or political unrest, for example. Reaching
200 suppliers on our Marketplace is a major milestone and
underscores our commitment to providing researchers with the exact
specimens that they need to complete their research in a timely,
effective, and compliant manner. Scaling the iSpecimen Marketplace
is a vital element of our growth strategy for today and in the
future.”
iSpecimen providers consist of hospitals, clinics, labs,
biorepositories, and clinical trial management organizations
dedicated to streamlining biospecimen procurement. To participate
on the iSpecimen Marketplace, suppliers are rigorously vetted to
meet industry standards and requirements, and must:
- Specify the permitted uses of the specimens that they provide
in accordance with the consent level granted by patients when
required.
- Comply with Institutional Review Board (IRB) or ethics
committee-approved protocols, as well as other regulations and good
clinical practices that guide biospecimens’ collection and
use.
- Demonstrate proper specimen processing, storage equipment and
handling procedures.
- Compliantly de-identify specimens and data.
- Agree to bi-annual audits for capabilities and annual
monitoring for regulatory compliance.
About iSpecimeniSpecimen (Nasdaq: ISPC) offers
an online marketplace for human biospecimens, connecting scientists
in commercial and non-profit organizations with healthcare
providers that have access to patients and specimens needed for
medical discovery. Proprietary, cloud-based technology enables
scientists to intuitively search for specimens and patients across
a federated partner network of hospitals, labs, biobanks, blood
centers and other healthcare organizations. For more information,
please visit www.ispecimen.com.
Forward Looking StatementsThis press release
may contain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Such
forward-looking statements are characterized by future or
conditional verbs such as "may," "will," "expect," "intend,"
"anticipate," believe," "estimate" and "continue" or similar words.
You should read statements that contain these words carefully
because they discuss future expectations and plans, which contain
projections of future results of operations or financial condition
or state other forward-looking information.
Forward-looking statements are predictions, projections and
other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to the risk factors contained in
the Company's filings with the Securities and Exchange Commission,
which are available for review at www.sec.gov. Forward-looking
statements speak only as of the date they are made. New risks and
uncertainties arise over time, and it is not possible for the
Company to predict those events or how they may affect the Company.
If a change to the events and circumstances reflected in the
Company's forward-looking statements occurs, the Company's
business, financial condition and operating results may vary
materially from those expressed in the Company's forward-looking
statements.
Readers are cautioned not to put undue reliance on
forward-looking statements, and the Company assumes no obligation
and do not intend to update or revise these forward-looking
statements, whether as a result of new information, future events
or otherwise.
For further information, please contact:
Investor ContactKCSA Strategic
CommunicationsAllison SossiSpecimen@kcsa.com
Media ContactKCSA Strategic
CommunicationsCaitlin Kasunich / Raquel
ConaiSpecimen@kcsa.com
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Mar 2024 to Apr 2024
iSpecimen (NASDAQ:ISPC)
Historical Stock Chart
From Apr 2023 to Apr 2024